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Introduction
T-lymphocytes play an important role in the regulation of bone metabolism, particularly the bone resorption by osteoclasts [1] [2] [3] [4] . However, the reports on activated Tlymphocyte effects on osteoclastogenesis are still controversial. Activation of Tlymphocytes in different experimental models or human diseases has mostly been shown to stimulate osteoclast differentiation and bone resorption by production of cytokines such as receptor activator of NF-κB ligand (RANKL), interleukin (IL)-6, IL-7, IL-17 and tumor necrosis factor (TNF)-α  [2, [5] [6] [7] [8] [9] . On the other hand, T-lymphocytes secrete interferon (IFN)-γ, IL-4, IL-10, IL-13, and granulocyte-macrophage colonystimulating factor (GM-CSF), which mediate the inhibition of osteoclastogenesis from hematopoietic progenitors [2, 5, [10] [11] [12] [13] [14] . Although some of those inhibitory cytokines have been associated with T-lymphocyte activation, various in vitro modes of Tlymphocyte activation differentially affect osteoclastogenesis [2, 8, 10, 12] , and most in vivo models report the enhanced osteoclast formation upon T-lymphocyte activation [3, 6, 15, 16] .
T-lymphocytes have a role not only in osteoclast activation and bone resorption but also in modulation of multipotent monocyte/macrophage progenitor differentiation towards either bone or immune lineage, which is determined by ligand binding to cell-surface receptors, particularly receptor activator of NF-κB (RANK) for osteoclasts and Toll-like receptors (TLRs) for mononuclear phagocytes [17] . The interaction of RANK, expressed on osteoclast progenitors, with its ligand RANKL is crucial for osteoclastogenesis in the presence of monocyte-macrophage colony-stimulating factor (M-CSF) [6, 7, [18] [19] [20] . At the level of cell signaling, both RANK and TLRs activate the dimeric transcription factors NF-κB and activator protein (AP)-1. Transcription factor 6 c-Fos, a component of AP-1, plays a positive role in osteoclast but a negative role in macrophage and dendritic cell differentiation [17, 21, 22] . GM-CSF controls the bifurcation between osteoclasts and dendritic cells from common progenitors by regulating c-Fos expression [22, 23] .
To study the controversial effect of activated T-lymphocytes on osteoclastogenesis we used several activation protocols, including in vivo and in vitro alloactivation.
Activation by any mode suppressed osteoclastogenesis stimulated by RANKL and M-CSF in murine hematopoietic progenitors. To elucidate the mechanism by which in vitro and in vivo activated T-lymphocytes suppress the differentiation towards the osteoclast lineage from bone-marrow (BM) hematopoietic progenitors we identified the stage at which the suppressive effect was achieved and the expression profile of the treated progenitors. In contrast to some other studies, our findings clearly show that activated T-lymphocytes have a net inhibitory effect on osteoclast differentiation by diverting early hematopoietic progenitors towards dendritic cell differentiation through downregulation of RANK and c-Fos.
Materials and methods

Subjects and Samples
Twelve-week old C57BL/6J (H-2 b ) female mice were used in all experiments. Allogeneic CBA/J (H-2 k ) mice was used for allostimulation. Maintenance of animals and all experimental procedures were approved by the Ethics Committee of the Zagreb University School of Medicine.
T-lymphocyte preparation
Murine lymph node cells were depleted of non-T-lymphocyte populations using antiCD11b/anti-CD45R monoclonal antibodies (mAbs) (BD Pharmingen, San Jose, CA) and further separated by anti-CD4/anti-CD8 mAbs conjugated to magnetic beads (Dynel Biotech, Wirral, UK). Separated T-lymphocyte populations had the purity of >90% as confirmed by flow-cytometry.
Immunosuppressant pretreatment consisted of 1 hour-incubation at 37°C [24] with various concentrations (2.5 to 40 µg/mL) of cyclosporine A (CsA) (Sigma-Aldrich, Saint Louis, MO).
For activation, T-lymphocytes were pulsed during 15 minutes by concanavalin A (Con A) (Sigma-Aldrich), washed, and cultured for 24 hours. In some experiments Tlymphocytes were activated by a 24 hour-incubation with anti-CD3 (1 µg/mL; Caltag, Burlingame, CA) and anti-CD28 mAbs (0.5 µg/mL; BD Pharmingen). To inhibit proliferation, T-lymphocytes were treated with mitomycin C (Sigma-Aldrich) (20 min at 37°C) after Con A-pulse and 24 hour-culture. T-lymphocyte activation was confirmed by the expression of CD71, and changes in the cell-cycle using flow-8 cytometry [25] . Proliferation was assessed by the colorimetric MTT (Sigma-Aldrich) assay. Activated T-lymphocytes were co-cultured with BM cells or cultured alone to obtain conditioned medium needed to treat osteoclastogenic cultures (see the paragraph
Osteoclast-like cell cultures).
In vivo and in vitro alloactivation
For mixed lymphocyte reaction (MLR), T-lymphocytes were co-cultured with allogeneic mitomycin C-treated splenocytes (cell ratio 1:1) for 48 hours [24] . Tlymphocyte activation and proliferation were confirmed as described for mitogen pulse.
Conditioned medium of in vitro alloactivated T-lymphocytes was used to treat osteoclastogenic cultures. C57BL/6J mice were allostimulated in vivo by i.p. injection of allogeneic splenocytes (5×10 7 /mouse) followed by foot-pad restimulation with the same cells (10 7 /foot), 10 days after the first injection [25] . Untreated mice and mice treated with syngeneic splenocytes were used as controls. Allostimulated mice provided tibial BM for osteoclast cultures and regionally alloactivated (popliteal) lymph node for Tlymphocyte cultures. In vivo alloactivated T-lymphocytes were co-cultured with BM cells or additionally cultured for 24 hours to obtain conditioned medium needed to treat osteoclastogenic cultures.
Osteoclast-like cell cultures
For osteclast-like (OCL) cell generation, BM were cultured overnight (day -1) with 5 ng/mL rmM-CSF (R&D Systems, Abingdon, UK) in α-MEM/10% FCS (SigmaAldrich) to stimulate monocyte/macrophage lineage [25] , followed by harvesting of 
Flow-cytometry
Non-adherent BM cell differentiation in osteoclastogenic cultures (after 2.5 day-culture) was assessed by: PE-anti-CD115 (c-Fms), PE-anti-CD116 (GM-CSF receptor α) 
Gene expression analysis
RNA was extracted using a commercial kit (TriPure; Roche) from harvested Tlymphocytes (freshly isolated or cultured) or osteoclastogenic cultures (2.5 or 5 dayculture). Each sample was obtained from ≥ three animals/group. RNA (1 µg) was converted to cDNA and amplified (20 qPCR reactions (25 µL/well) were conducted in an ABI Prism 7000 Sequence Detection System (Applied Biosystems), in quadruplicate, as described previously [26] . According to the standard curve, the relative amounts of RNA for target genes were calculated as the ratio of the quantity of target gene normalized to β-actin. RNA quantity for control sample in each experiment was set as 1 and the relative RNA quantities for other samples were calculated in accordance to this value.
Statistics
Experiments were performed at least three times and the representative data were shown (mean ± SD of four replicates per sample). Statistical analysis of TRAP + OCL cell number was performed using ANOVA and Student-Newman-Keuls post-hock test (MedCalc, Mariakerke, Belgium). Relative values of RNA quantity were statistically analysed using the comparison of the means t-test with Bonferroni correction for multiple-group comparison (MedCalc). For all experimemts, α-level was set at 0.05.
Results
Activated T-lymphocytes inhibit murine osteoclast differentiation
T-lymphocyte were activated by a brief mitogen pulse [27] 
Inhibition of osteoclastogenesis is achieved by changes in cytokine gene expression by T-lymphocytes
As assessed by qPCR, activation of T-lymphocytes significantly increased the GM-CSF upon activation [29] . GM-CSF expression was specifically associated with Tlymphocytes, since we found increased GM-CSF RNA only in co-cultures of activated T-lymphocytes and non-adherent BM cells and not in non-adherent BM cell cultures treated with activated T-lymphocyte conditioned medium (data not shown).
Osteoclast precursors treated with mitogen activated T-lymphocytes or culture supernatants express lower level of RANK, CD115 and calcitonin receptor
We further assessed the expression of RANK and CD115, receptors for essential osteoclastogenic factors RANKL and M-CSF respectively [30] , and found that the RNA for RANK and CD115 were significantly lower in 2.5 day-osteoclatogenic cultures 15 treated with activated T-lymphocytes or conditioned medium compared with control cultures (Figure 4) . At day 5, the decrease in gene expression was more pronounced for RANK than for CD115, and was stronger in cultures treated with activated Tlymphocytes than with conditioned medium. Moreover, expression of c-Fos, transcription factor important for osteoclast lineage commitment [17] , and CtR, marker of the differentiated osteoclast [21] , was suppressed upon treatment with activated Tlymphocytes or conditioned medium (Figure 4 ). Flow-cytometry showed a downregulation of RANK and CD115 expression on day 2.5 after the addition of activated T-lymphocyte conditioned medium to osteoclastogenic cultures ( Figure 5A ).
Increased GM-CS expression mediates transdifferentiation between osteoclast and dendritic lineages
To test if activated T-lymphocytes could suppress osteoclast differentiation by GM- 
Allogeneic stimulation of T-lymphocytes in vitro and in vivo produces similar effects on osteoclastogenesis as activation by mitogen or anti-CD28/CD3 Abs
In addition to mitogen and anti-CD3/CD28 stimulation, which has been commonly used to study the effects on osteoclastogenesis [6, 8, 12] , we also performed T-lymphocyte Figure 6D ). Pattern of RANK and CD115 expression was similar among experimental and control groups when allostimulation, anti-CD3/CD28 treatment or Con A-pulse were used for T-lymphocyte activation (see Figure 4 ). All modes of T-lymphocyte activation were associated with an approximate 5-6 fold increase in GM-CSF expression (see Figure 2) .
CsA abrogates inhibitory effect of T-lymphocytes on osteoclastogenesis
We further tested if immunosuppressants CsA, which inhibits T-lymphocyte activation, can overcome the suppression of osteoclastogenesis caused by Con A-pulsed Tlymphocytes. Since T-lymphocytes and osteoclasts share the sensitivity to many common cytokines [1, 2, 5] and suppressory signals, including CsA [32, 33] , we wanted to separate the effect of CsA on T-lymphocytes from the effect on osteoclast progenitors and, therefore, used CsA only for a brief pretreatment of T-lymphocytes and not for actual culture [24] . A brief 1 hour-preincubation of T-lymphocytes with different doses of CsA (2.5, 10, and 40 µg/mL) were performed prior to Con A-pulse and subsequent 
Discussion
Our study demonstrated that activated T-lymphocytes suppressed hematopoietic cell differentiation towards the osteoclast lineage by affecting the lineage commitment of early monocyte/macrophage progenitors through the mechanism that involved RANK downregulation and c-Fos suppression. In addition to mitogen-pulse and anti-CD3/CD28 Abs, we used in vitro and in vivo T-lymphocyte alloactivation and showed for the first time that these methods also produce inhibition of osteoclastogenesis. The stage of osteoclast differentiation was crucial for the inhibitory action of activated Tlymphocyte on osteoclastogenesis, since the suppressive effect was visible only on early osteoclast progenitors when activated T-lymphocytes were added with RANKL and M-CSF at the beginning of the osteoclastogenic cultures but not on committed osteoclasts.
The inhibitory effect was specifically associated with T-lymphocyte activation and not proliferation, and did not depend on cell-to-cell contact. The important mediator of osteoclast inhibition and dendritic lineage stimulation in our study was GM-CSF, known to regulate the bifurcation between osteoclast and dendritic cell lineages [22] .
We found that activated T-lymphocytes upregulated GM-CSF expression and that the osteoclast-inhibitory effect of activated T-lymphocytes was abrogated by the addition of anti-GM-CSF Abs to osteoclatogenic cultures.
GM-CSF effect on osteoclastogenesis depends on the experimental model and the duration or timing of GM-CSF administration, and was differently reported in various animal models in vivo and osteoclast cultures in vitro [11] [12] [13] 22, 32, [34] [35] [36] . In contrast to the study by Wyzga et al [12] , who claimed that the mode of T-lymphocyte activation is crucial for the final effect on osteoclast differentiation, we confirmed that the stage of osteoclast precursors is more important by showing that GM-CSF in the presence of RANKL at the beginning of the osteoclastogenic cultures inhibits osteoclast formation through cellular differentiation into dendritic cells, whereas is ineffective after the commitment of RANKL-induced differentiation towards osteoclasts. It has already been shown that GM-CSF treatment of early human osteoclast precursors blocks osteoclastogenesis [34] , with a repression of major genes indicative of osteoclast functions [32] , but those studies did not investigate activated T-lymphocytes as a possible source of GM-CSF in this regulation. Among other effects, GM-CSF inhibits c-Fos in osteoclast progenitors, which disrupts the RANK/c-Fos/nuclear factor of activated T cells (NFAT)c1 transcriptional cascade critical for osteoclastogenesis [17] .
IFN-γ also suppresses osteoclastogenesis by disrupting RANKL-induced activation of NF-κB and JNK [1, 5] . Nevertheless, increased IFN-γ expression by activated Tlymphocytes was not important in our model, since osteoclast inhibition was achieved at the level of decreased RANK expression (upstream of the described IFN-γ action) and conditioned medium, which has not been found in control cultures. This supports a previous finding that GM-CSF stimulates osteoclast progenitor proliferation but inhibits differentiation, and in combination with RANKL promotes dendritic cell formation [22, 23, 34] . The mechanism underlying the differentiation switch between osteoclast and dendritic lineages certainly involves the regulation of transcription factors essential for osteoclast formation, including c-Fos [37] . c-Fos expression was downregulated in cultures treated by activated T-lymphocytes, showing that osteoclast differentiation is inhibited and dendritic cell differentiation reciprocally stimulated through the suppression of c-Fos, supporting our hypothesis that progenitor commitment toward lineages other than osteoclast is the underlying mechanism of osteoclast inhibition in our model.
By analyzing RANK and CD115 during in vitro differentiation [30] , we found that the inhibitory effect of activated T-lymphocytes was more pronounced on RANK expression compared to CD115 expression. This suggests that downregulation of RANK signaling is the major mechanism of activated T-lymphocyte action, since RANK expression on hematopoietic progenitors is essential for osteoclast differentiation and activation [19] [20] [21] . CD115 gene was downregulated in cultures treated with activated T-lymphocytes at earlier stages of osteoclast differentiation, confirming that CD115 tyrosine kinase provides signals required for survival and proliferation of early osteoclast progenitors [21, 30] . Studies using different osteoclast culture systems reported different findings regarding the expression of CD115, RANK, and CD116 in the presence of M-CSF, GM-CSF, or IL-3 [22, 32, 36, 37] . In contrast to 21 showed upregulation of CD115 upon GM-CSF treatment of human mononuclear cell cultures [32] , we detected a similar CD116 level irrespective of the treatment with activated T-lymphocytes, suggesting that the inhibition of osteoclastogenesis is not regulated by CD116 expression.
In addition to T-lymphocyte activation in vitro by mitogen-pulse or anti-CD3/CD28 Abs, we extended the importance of our findings by showing that T-lymphocytes alloactivated in vitro and in vivo also exerted a suppressive net-effect on osteoclastogenesis. These results have clinical significance, since bone homeostasis is often severely disturbed after organ transplantation that involves T-lymphocyte alloactivation [38, 39] . Moreover, we confirmed that activated T-lymphocytes can suppress osteoclastogenesis in BM in vivo by the experiments where we used in vivo alloactivation by i.p. injection and regional foot-pad restimulation with allogeneic cells.
When we cultured native non-adherent BM cells from these mice, osteoclastogenesis was significantly suppressed compared with cultures from unstimulated animals. These findings confirmed the complex function of cytokine expression patterns in the interplay between T-lymphocytes and osteoclast progenitors in BM environment despite a negligible presence of mature T-lymphocytes in BM [4, 10] .
The inhibitory effect of T-lymphocyte activation on osteoclastogenesis was abolished by T-lymphocyte pretreatment with immunosuppressant CsA. CsA action leads to the inhibition of NFAT and, hence, suppression of the transcription of IL-2 and other cytokine genes, including GM-CSF [24, 33, 40] . T-lymphocyte treatment with CsA prior to the Con A-pulse downregulated GM-CSF expression, which is consistent with the presence of NFAT response element in the enhancer part of GM-CSF transcriptioncontrol region [13, 41] . In addition, we found only an insignificant decrease in RANKL expression after CsA pretreatment, although a previous study reported that CsA potently blocked RANKL in T-cell hybridoma A1.1 [7] . Observed changes in the cytokine pattern produced by T-lymphocytes upon immunosuppressive treatment may contribute to the post-transplantation osteoporosis in patients receiving long term immunosuppressive treatment [38, 39] .
Although it is known that the immune system has powerful effects on bone resorption, 
